Daily BriefsEquity Bottom-Up

Daily Brief Equity Bottom-Up: US Masters (URF AU): Almost Too Good To Be True and more

In today’s briefing:

  • US Masters (URF AU): Almost Too Good To Be True
  • Boeing: Turbulent Times – [Business Breakdowns, EP.129]
  • Money Forward (3994) | A Deep Dive into the Corporate Business
  • Country Garden’s Offshore Debt Issuance Structure May Be Less Favorable than that of Evergrande
  • Douzone Bizon: Cooperating with Amazon Web Services to Enter the Global SaaS Market
  • SoftBank Group (9984 JP): More Downside Risk to the NAV than Upside Potential
  • Triveni Turbine Ltd- Forensic Analysis
  • Las Vegas Sands: A Clear Cut Buy on the Dip Strategy as Asia Gaming Recovery Gains Strength
  • Philippines Exchange (PSE PM): Deep Value Exchange With Growth Option Embedded
  • Medikaloka Hermina (HEAL IJ) – Starting Patients Young


US Masters (URF AU): Almost Too Good To Be True

By David Blennerhassett

  • US Masters Residential Property Fund (URF AU), an ASX-listed real estate trust investing in single-family homes in gentrifying New York metropolitan neighbourhoods  – what could go wrong? 
  • Quite a lot, apparently. Shares are down bigly from the 2011 listing; the responsible entity faced ASIC-backed court proceedings for misleading clients; plus dissent emerged over appointing a new RE. 
  • URF is gradually offloading its entire portfolio, and buying back shares, which are trading at 0.49x price-to-book.  So, where’s the rub?

Boeing: Turbulent Times – [Business Breakdowns, EP.129]

By Business Breakdowns

  • Boeing is a globally recognized company in the aerospace industry that was founded in 1916 by William Boeing.
  • The company’s business model includes three segments: commercial, defense, and services, with the commercial segment being the largest, accounting for nearly 40% of its revenues.
  • Boeing has played a crucial role in the evolution of the aviation industry, from fabric airplanes to carbon fiber composite jetliners that can fly long distances without stopping.

This podcast is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.


Money Forward (3994) | A Deep Dive into the Corporate Business

By Mark Chadwick

  • Money Forward’s Corporate SaaS business is thriving, with +44% year-over-year growth in ARR, a 139,000-strong customer base, and a healthy CAC-to-LTV ratio of 3.7x.
  • Despite strong fundamentals, the stock’s 20% decline is attributed to market fixation on quarterly earnings and concerns about rising interest rates.
  • The company’s untapped potential lies in the mid-market segment, where cross-selling opportunities across 18 paid products could significantly boost ARPA, tapping into a TAM estimated at $15 billion.

Country Garden’s Offshore Debt Issuance Structure May Be Less Favorable than that of Evergrande

By Fern Wang

  • Country Garden’s offshore debt default is happening. Its time to investor to revisit their position as restructuring is looming.
  • Investors may not have any access to Country Garden’s onshore assets under its current offshore issuance structure.
  • Evergrande’s offshore debt issuing structure could be more favourable compared to that of Country Garden in bankruptcy, depending on how the court interprets its Keepwell agreement.

Douzone Bizon: Cooperating with Amazon Web Services to Enter the Global SaaS Market

By Douglas Kim

  • On 16 October, Douzone Bizon (012510 KS) announced that it is entering the global software-as-a service (SaaS) market in cooperation with Amazon Web Services (AWS). 
  • The agreement stipulates that Douzone Bizon will develop global SaaS through AWS support and enter overseas markets. 
  • We believe shares of Douzone Bizon have been oversold. Valuations have become more attractive and its cooperation with AWS is also likely to improve the company’s overseas sales and profits. 

SoftBank Group (9984 JP): More Downside Risk to the NAV than Upside Potential

By Victor Galliano

  • There is downside risk to SoftBank’s NAV, due to valuations relating to Arm and the Vision Funds including LatAm; on aggregate, these holdings account for 70% of group equity value
  • We believe that Arm’s super-premium valuation is unsustainable; there is lack of transparency on the valuations relating to the unlisted Vision Fund holdings, especially in SVF2
  • We estimate that SoftBank shares trade at a 44% NAV discount, tighter than the average at the end of the last eight quarters; add to this Arm’s current over valuation

Triveni Turbine Ltd- Forensic Analysis

By Nitin Mangal

  • Triveni Turbine (TRIV IN)  is one of the leading players in manufacturing of steam turbines, which in turn has uses across various energy intensive industries. 
  • The company has recovered well from covid, has a robust order book in conjuction with healthy financial position. Balance sheet is debt-free, high cash and lean WC cycle. 
  • The only possible risk that comes to the balance sheet would be of potential statutory disputes. The contingent liabilities remain under-stated.

Las Vegas Sands: A Clear Cut Buy on the Dip Strategy as Asia Gaming Recovery Gains Strength

By Howard J Klein

  • Our long held strong conviction on  LVS has not faltered despite its chronically undervalued.
  • Monthly gross gaming win trends do not reflect sagging China economy.
  • Imminent 3Q23  earnings release may well  hold upside surprises. We sense a beat.

Philippines Exchange (PSE PM): Deep Value Exchange With Growth Option Embedded

By Sameer Taneja

  • Philippine Stock Exchange (PSE PM) is a monopoly making >60%>/45% EBITDA/NPAT margins across its history with ex-cash ROCE’s >30% (cash at five bn pesos is 33% of market cap).
  • With a relatively low penetration of brokerage accounts (1.5%), an underowned market with 100mn USD volume, and low fee structures, there is ample low-hanging fruit on earnings growth.
  • The stock trades at 18x PE (9x ex-cash and real estate). With an 80-100% payout, the dividend yield is 5-6%, so you are paid to wait for future catalysts. Our meeting with management in Manila last week gives us added confidence. 

Medikaloka Hermina (HEAL IJ) – Starting Patients Young

By Angus Mackintosh

  • Medikaloka Hermina (HEAL IJ) remains a differentiated hospital player in Indonesia given its focus on the treatment of women and children plus its doctor partnership model in its hospitals.
  • The company booked a strong rebound in both inpatient and outpatient volumes in 1H2023, and we expect this to continue into 2H, with two new hospitals opened in 3Q2023.
  • Despite exhibiting the strongest growth amongst its peers, the company still trades at a significant discount to Mitra Keluarga Karyasehat Tbk (MIKA IJ) on 10.2x FY2024E EV/EBITDA. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars